Pregabalin Capsule
Product Images NDC 63629-8196

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8196). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298196)

Label for Pregabalin Capsules, USP 75 mg by Bryant Ranch Prepack. The label shows the strength as 75 mg, package size of 30 capsules, and includes storage instructions to keep at 20°-25°C (68°-77°F). The label displays the NDC 63629-8196-01 and the BRP Pharmaceuticals logo.*

FDA Label Image

Label (Lbl6362981962)

Pregabalin 75 mg capsule packaging label from Bryant Ranch Prepack. The label states the product is an orange capsule with the designation (CV) and compares to Lyrica 75 mg capsules by ScieGen Pharmaceuticals. The package contains 30 capsules and includes storage instructions at 20°-25°C. NDC 63629-8196 is visible on the label along with a barcode and lot number.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percent of patients improved by percent improvement in pain from baseline, comparing Pregabalin at 200 mg, 100 mg, 25 mg three times a day, and placebo. The x-axis indicates percent improvement in pain, and the y-axis shows percent of patients improved. Multiple dose responses for Pregabalin and placebo are differentiated by line styles.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Two lines compare Pregabalin 100 mg three times a day and placebo, with the Pregabalin group showing a higher percentage of patient improvement across increasing levels of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Four lines represent Pregabalin dosages of 75 mg, 150 mg, 300 mg twice daily, and placebo, showing the comparative improvement rates at various pain improvement percentages up to 100.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph tracks patient improvement percentages from 0 to 100 percent on the x-axis and 0 to 100 percent of patients improved on the y-axis.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. Three lines represent Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating their comparative effects on patient pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph showing responder rates (%) from two clinical studies labeled Study E1 and Study E3. The x-axis displays treatment groups with various dosages and placebo, and the y-axis shows responder rates from 0% to 60%. Both studies show increasing responder rates with higher dosages, with statistical significance indicated versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A dose-response line graph showing seizure reduction as median percent change from baseline versus dose in mg/day for Pregabalin. Four study groups labeled E1 BID, E2 TID, E3 BD, and E3 TID are plotted with symbols and show increasing seizure reduction with dose. Statistically significant p-values are noted for comparisons with placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph comparing the percent improvement in pain from baseline against the percent of patients improved for different doses of Pregabalin (800 mg, 450 mg, 300 mg daily doses) and placebo. The x-axis shows percent improvement in pain from baseline, the y-axis shows the percent of patients improved, with four distinct lines representing each treatment group.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier curve graph comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The y-axis shows the estimated percentage without LTR from 0% to 100%, and the x-axis shows days from 0 to 180. The solid line represents Pregabalin, showing higher percentages without LTR over time compared to the dashed line for placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph showing the percent of subjects improved over a range of percent improvement from baseline to week 12 BOCF. The x-axis represents percent improved from baseline to week 12, ranging from greater than 0 to 100 percent. The y-axis represents the percent of subjects improved, ranging from 0 to 100 percent. Two lines are shown: a solid line for Pregabalin and a dotted line for placebo, illustrating a higher percentage of subjects improved with Pregabalin compared to placebo across the range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph showing percent of subjects improved versus percent improved from baseline to week 16 BOCF. Two lines are displayed: one solid line for Pregabalin and one dashed line for Placebo, indicating comparison of improvement rates over a percentage scale from 0 to 100 percent.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula illustrating the calculation of creatinine clearance (CLcr). The formula includes variables for age, weight, serum creatinine, and a multiplier adjustment for female patients (0.85).*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure depicting the molecular formula of Pregabalin. The diagram shows the arrangement of atoms, including a carboxylic acid group (CO2H) and an amine group (NH2) attached to a branched carbon chain, representing the active ingredient Pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.